New collaboration between the EMA and the FDA

The two regulatory bodies have decided to launch a joint initiative in order to share information on inspections of bioequivalence studies of generics. An 18-month pilot phase will see joint inspections for approval applications submitted to the two bodies. A previous collaboration between the EMA and the FDA concerning GCP (Good Clinical Practice) was successfully carried out in 2009.